Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.
Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.
复制标题
DOI：
10.1080/10826084.2020.1858106
复制
发表时间：
2021
影响因子：
2
通讯作者：
Neighbors CJ
中科院分区：
文献类型：
--
作者：
Choi S;Healy S;Shapoval L;Forthal S;Neighbors CJ
尽管美国阿片类药物使用障碍(OUD)的迅速增加和丙型肝炎病毒(丙型肝炎病毒)的同时增加是有充分证据的，但对高危人群中的丙型肝炎病毒检测知之甚少。我们检查了纽约OUD患者在OUD治疗环境中的丙型肝炎病毒检测模式。使用2014年纽约医疗补助索赔数据，我们确定了受益人中的OUD诊断、OUD治疗(美沙酮、丁丙诺啡、纳曲酮)、其他治疗(住院或门诊非以药物为基础的心理社会治疗，如心理治疗和不治疗)的使用情况和丙型肝炎病毒检测状况。我们进行了多变量Logistic回归分析，以确定在各种治疗环境中与丙型肝炎病毒筛查相关的因素。2014年，确认了79,764名被诊断为OUD的人。接受美沙酮、丁丙诺啡、纳曲酮、其他治疗和未接受治疗的患者的丙型肝炎病毒筛查患病率分别为32.4%、16.2%、20.6%、16.8%和18.1%。在调整后的Logistic回归分析中，接受任何OUD治疗的患者被筛查的几率更高，其中美沙酮患者的几率最高。参与OUD的药物治疗与增加丙型肝炎病毒检测有关。研究结果表明，获得以药物为基础的治疗对OUD很重要，需要进一步提高丙型肝炎病毒筛查率。
Although the rapid increase in opioid use disorders (OUD) and concurrent increase in Hepatitis C virus (HCV) in the United States is well-documented, little is known about HCV testing among high-risk populations. We examine patterns of HCV testing across OUD treatment settings for individuals with OUD in New York. Using 2014 New York Medicaid claims data, we identified OUD diagnosis, OUD treatment (methadone, buprenorphine, naltrexone, other treatment (inpatient or outpatient non-medication-based psychosocial treatment, such as psychotherapy) and no treatment) utilization and HCV-testing status among beneficiaries. We performed multivariable logistic regression to identify factors associated with HCV screening across OUD treatment settings. 79,764 individuals with OUD diagnoses were identified in 2014. The prevalence of HCV screening was 32.4%, 16.2%, 20.6%, 16.8%, and 18.1% for those receiving methadone, buprenorphine, naltrexone, other treatment, and no treatment, respectively. In the adjusted logistic regression, those receiving any OUD treatment had greater odds of being screened, with the highest odds among methadone clients. Engagement in medication for OUD is associated with increased HCV testing. Findings indicate the importance of access to medication-based treatment for OUD and a need to further improve HCV screening rates.
登录
查看更多内容
影响因子：
3.9
作者：
Carey, Katelyn J.;Huang, Wei;Tsui, Judith I.
通讯作者：
Tsui, Judith I.
影响因子：
33.7
作者：
Schillie, Sarah;Wester, Carolyn;Ryerson, A. Blythe
通讯作者：
Ryerson, A. Blythe
影响因子：
5.5
作者：
Gordon, Adam J.;Lo-Ciganic, Wei-Hsuan;Donohue, Julie M.
通讯作者：
Donohue, Julie M.
DOI：
10.15585/mmwr.mm6638a3
发表时间：
2017-09-29
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Flanigan CA;Leung SJ;Rowe KA;Levey WK;King A;Sommer JN;Morne JE;Zucker HA
通讯作者：
Zucker HA
影响因子：
39.2
作者：
Korthuis PT;McCarty D;Weimer M;Bougatsos C;Blazina I;Zakher B;Grusing S;Devine B;Chou R
通讯作者：
Chou R